Phathom Pharmaceuticals (NASDAQ:PHAT) Receives “Buy” Rating from Guggenheim
Guggenheim restated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note published on Wednesday,Benzinga reports. Several other equities analysts have also recently issued reports on PHAT. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report […]
Guggenheim restated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note published on Wednesday,Benzinga reports. Several other equities analysts have also recently issued reports on PHAT. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report […]
